The Department of Veterans Affairs (VA) awarded an Indefinite Delivery Contract (IDC) worth up to $64,296,441 to Tempus AI, Inc. (doing business as Tempus Labs Inc.) for tumor normal matched genomic testing services. Tempus, a technology company specializing in precision medicine and genomic sequencing, will use its expertise in comprehensive genomic profiling and analysis to support the VA's precision oncology initiatives for veteran cancer patients.
Under this IDC, the VA issues firm fixed price delivery orders for Tempus to analyze genomic sequencing data from tumor and normal tissue samples of veterans. This enables the VA to leverage Tempus' capabilities on an ongoing basis to inform precision medicine treatment decisions. Delivery orders issued to date range from $325,119 to $5,999,647, demonstrating the consistent and substantial nature of Tempus' support to the VA's genomic testing needs. The services are performed at Tempus' facilities in Fredericksburg, Virginia and Chicago, Illinois, with no subcontractors involved. This contract supports the VA's efforts to improve cancer care for veterans through precision oncology approaches.
Generated 1/28/25, 12:06 PM